Details for Patent: 8,916,195

Which drugs does patent 8,916,195 protect, and when does it expire?

Patent 8,916,195 protects CONTRAVE and is included in one NDA.

This patent has twelve patent family members in six countries.

Summary for Patent: 8,916,195

Patent landscape, scope, and claims:

Title:	Sustained release formulation of naltrexone
Abstract:	A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
Inventor(s):	McKinney; Anthony A. (San Diego, CA), Tollefson; Gary D. (Indianapolis, IN), Soltero; Richard (Holly Springs, NC), Dunzo; Thea Elise (Durham, NC)
Assignee:	Orexigen Therapeutics, Inc. (La Jolla, CA)
Application Number:	11/757,773
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,916,195
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form;

Drugs Protected by US Patent 8,916,195

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014		RX	Yes	Yes						USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY

International Family Members for US Patent 8,916,195

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	061233
European Patent Office	2061448
European Patent Office	3626236
Spain	2749800
Japan	2009539837